Peptilogics' PLG0206 represents a breakthrough innovation in infectious disease. First drug designed specifically to penetrate and kill biofilm-protected bacteria. RETAIN Phase 2/3 trial now enrolling patients with prosthetic joint infection. The previous phase showed 93% infection-free rate. It could revolutionize the treatment of medical device-related infections.
